NEW YORK(GenomeWeb) – Molecular diagnostics firm Biofortuna has raised £1.5 million ($2.2 million) in its latest private funding round, the company announced today.

Based in the UK, Biofortuna offers contract in vitro diagnostics development, lyophilization, and stabilization services in its FDA- and ISO13485-approved facilities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.